Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note One woman’s pregnancy shows how this distinction matters

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.

July 02, 2026

Vol.52 No.26

By Paul J. Limburg

Trials & Tribulations

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Labcorp and the Alliance for Clinical Trials in Oncology will collaborate on a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA grants Fast Track designation to Suplexa in MSI-H CRC

FDA granted Fast Track designation to Suplexa, a differentiated, non-engineered autologous treatment, for the treatment of patients with colorectal cancer of the MSI-H phenotype.

May 15, 2026

Vol.52 No.19

Clinical Trials & Tribulations

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

Vol.52 No.12

By W. Kimryn Rathmell

Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

Vol.52 No.12

By Richard M. Goldberg

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note

One woman’s pregnancy shows how this distinction matters

YOU MAY BE INTERESTED IN

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Renew today!

Subscriber content

Never miss an issue!

Login

Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note

One woman’s pregnancy shows how this distinction matters

YOU MAY BE INTERESTED IN

Is it time to re-assess the practice and practicality of screening colonoscopy?Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancerNew guidelines offer another option

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Never miss an issue!

Login

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt